Evaluation of the Safety of Lead Compounds for Allergic Asthma

哮喘是发达国家最常见的慢性呼吸道疾病之一，通常用皮质类固醇治疗，皮质类固醇提供症状缓解和基础疾病的粗略非特异性治疗。我们正在通过靶向参与哮喘炎症机制的不同酶HPGD 2S来寻求创新疗法。我们已经开发出有效的抗炎药物候选药物，并旨在在进入临床研究之前对这些化合物的安全性进行评估。

Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.